Cellectis bioresearch and Lonza Enter Development and Commercial Manufacturing Agreement
09-Jun-2010
- France
Cellectis bioresearch will use its meganucleases to deactivate (knock-out) the glutamine synthetase (GS) in CHOK1SV, Lonza’s proprietary host cell line. Meganucleases are molecular scissors that can be directed to a single highly specific site in the genome of a cell, thereby allowing a wide range of precise genome modifications, including targeted gene integration, gene knock-out as well as modulation of gene function.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.